Gero Named World Economic Forum 2026 Technology Pioneer for Advancing the Physics of Aging in Drug Discovery
Gero, a physics-first AI drug discovery company developing therapeutics for age-related disease and aging biology, today announced that it has been named a 2026 Technology Pioneer by the World Economic Forum.
How Will We Defeat Aging? Scientific Debate Ends with $10,000 Cash Prize and Surprising Verdict, Signaling New Investment Opportunities
A landmark debate titled "How to Defeat Aging," held by Open Longevity at the Foresight Institute on May 27, 2024, produced an unexpected winner, uncovering a far more nuanced narrative behind the recent surge of interest to rejuvenation biotechnology. The event pitted two leading scientists Dr. Aubrey de Grey and Dr. Peter Fedichev against each other, each offering contrasting perspectives on the future of aging research.
Physics-Powered GenAI Biotech Gero Raises $6M to Find Root Causes of Aging and Age-Related Diseases
Gero, a biotechnology company focused on aging and chronic diseases, has closed $6M in a Series A extension round. This funding round positions Gero to continue internal drug development programs, grow its scientific team to boost platform technology development, and expand its US presence.
Longevity Biotech Gero Entered a Research Collaboration With Pfizer to Discover Potential Targets for Fibrotic Diseases
Gero today announced that it has entered into a research collaboration with Pfizer to apply Gero’s machine learning technology platform to discover potential therapeutic targets for fibrotic diseases using large-scale human-based data.
